Gri bio reports third quarter 2024 financial results and outlines progress towards clinical data readout of gri-0621 in ongoing phase 2a study for idiopathic pulmonary fibrosis

$13.9 million in gross proceeds raised since the beginning of 2024 extending expected cash runway into mid q1 2025 and through interim data readout from gri-0621 phase 2a biomarker study

GRI Ratings Summary

GRI Quant Ranking